Amgen wins FDA nod for Lumakras

Amgen gets colorectal cancer okay for KRAS drug
The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for adults with KRAS G12C-mutated metastatic colorectal cancer (CRC) who have been previously treated with chemotherapy.
Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer
The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRASG12C inhibitor Lumakras as part of a combination regimen for adults with metastatic colorectal cancer (mCRC) whose tumors harbor an abnormal gene known as KRAS G12C.
FDA Approves Lumakras with Vectibix in KRAS G12C+ Colorectal Cancer
The FDA has approved Lumakras with Vectibix for adults with KRAS G12C-mutated metastatic colorectal cancer who received chemotherapy.
FDA Approves Sotorasib Plus Panitumumab for KRAS G12C-Mutated Metastatic CRC
The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free survival.
FDA Approves Sotorasib and Panitumumab Combination: Doubling Survival for KRAS G12C-Mutated Colorectal Cancer
The FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS G12C-mutated metastatic colorectal cancer.
Looking Beyond Obesity, Amgen Wins Colorectal Cancer Expansion for Lumakras
The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic colorectal cancer, but in its approval announcement, the FDA pointed to significant improvements in progression-free survival,
Sotorasib Plus Panitumumab Receives FDA Approval for KRAS G12C–Mutated Colorectal Cancer
The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) whose disease progressed after chemotherapy.
FDA Oks Sotorasib/Panitumumab in KRAS G12C-Mutant Colorectal Cancer
The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with previously treated KRAS G12C-mutated colorectal cancer (CRC). The approval is supported by data from the CodeBreaK 300 (NCT05198934) study.
FDA nod for Lumakras with Vectibix combo for mCRC
The US Food and Drug Administration approved sotorasib (trade name Lumakras) with panitumumab Vectibix), from US biotech major Amgen, for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC),
Amgen: FDA Approves Lumakras (sotorasib) In Combination With Vectibix (panitumumab) For Chemorefractory Kras G12c-mutated Metastatic Colorectal Cancer
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/
Amgen's Lumakras+Vectibix Combo Gets FDA Approval For Metastatic Colorectal Cancer Treatment
Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC C…
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in ...
Healio1d
FDA approves therapies for colorectal cancer, mantle cell lymphoma
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...